Blockage of Eosinopoiesis by IL-17A Is Prevented by Cytokine and Lipid Mediators of Allergic Inflammation

Figure 2

Dependence of IL-17A on iNOS and synergism between IL-17A and exogenous NO in iNOS-deficient bone-marrow. Bone-marrow cultures were established with IL-5, alone or in association with IL-17A, from wild-type (WT) control (C57BL/6, white bars) and iNOS-deficient (iNOS-KO, black bars) mutant C57BL/6 mice (a, c) or from BALB/c wild-type mice (b) or from CD95-deficient lpr mutant BALB/c (d), as described in legend of Figure 1. Data (mean ± SEM), (a, c, and d), (b), are the numbers of EPO+ cells recovered at day 7. (a) Concentration-response relationship for IL-17A on WT and iNOS-deficient bone-marrow. (b) Blockade of IL-17A effect by iNOS-selective inhibitor aminoguanidine (AmGua). (c) Concentration-response relationships for IL-17A and SNP, separately and in combination, in wild-type and iNOS-deficient bone-marrow, showing synergism between IL-17A (1 ng/mL) and NO donor SNP (10⁻⁴ M) in iNOS-deficient bone-marrow. (d) Dependence of IL-17A effectiveness on CD95 (comparing with (b), white bar and first black bar). and for the differences between the indicated points or in (b), relative to the respective IL-5 (negative) controls.

(a)

(b)

(c)

(d)